Dual targeting CAR T cells for multiple myeloma and its immunosuppressive microenvironment

Lab's research themes:

Our strategies to boost T cell avidity and thus, improve ATT converge at the final steps of effector functions, as mediated by the secretion of cytotoxic molecules. Moreover, our work is devoted to the elucidation of tumor-stroma interactions in hematological diseases.
Studying cell biological mechanisms that define the capacity of T cells to mediate protection from infections or tumors, we have identified gene functions that amplify the secretion of effector molecules. Because a high local effector function of adoptively transferred T cells (ATT) is key for tumor eradication, this approach can complement current efforts to select for tumor-antigen specific T cells.
We combine animal models, cellular and molecular biology techniques as well as gene expression profiling to gain insight into the complex network of tumor cells and a benign infrastructure within secondary lymphoid organs. These approaches are instrumental in gaining a profound understanding of mechanisms that cause lymphoma to be addicted to the local microenvironment.

Merits of the lab:

The Rehm Lab is widely recognized for its pioneering research in the areas of cell death, survival pathways, and cancer therapy. The lab’s contributions, particularly in understanding the molecular mechanisms underlying Hodgkin Lymphoma and other lymphomas, have significantly advanced both basic science and clinical oncology. Their work on deregulated transcription factors and survival mechanisms has led to new potential therapeutic targets and strategies, including advancements in CAR T cell therapy, which holds promise for improving patient outcomes in these challenging cancers.
One of the lab's key merits is its interdisciplinary approach, which combines expertise in molecular biology, genetics, and immunology to address complex research questions. By employing advanced technologies such as CRISPR/Cas9 gene editing and developing innovative approaches in CAR T cell therapy, the Rehm Lab is able to dissect the intricate signaling networks that govern cell death and survival with a high degree of precision. This focus on cutting-edge research tools and translational potential ensures that their discoveries are both scientifically robust and clinically relevant.
The Rehm Lab is also distinguished by its strong collaborative ethos. The team works closely with other research groups at the MDC and with clinical partners in hematology and oncology to ensure that their research addresses critical clinical challenges. This collaborative environment not only enhances the impact of their research but also provides an excellent training ground for PhD students and postdoctoral researchers, who gain exposure to a broad spectrum of techniques, research questions, and clinical applications.
In addition to its scientific achievements, the Rehm Lab is committed to fostering the next generation of researchers. The lab provides a supportive and dynamic environment for young scientists, emphasizing both the development of technical skills and the cultivation of critical thinking. This dedication to education, combined with the lab’s innovative research, makes it an exceptional place for aspiring scientists to develop their careers.

Why do we train medical doctors in our team?

We train medical doctors in our team to integrate basic research with clinical practice, facilitating the translation of our findings into effective therapies through close collaborations with clinicians, hospitals, and patient networks.. Armin, the group leader is a physician scientist himself.

The position